» Articles » PMID: 37014500

The Predictive Value of [F]FDG PET/CT Radiomics Combined with Clinical Features for EGFR Mutation Status in Different Clinical Staging of Lung Adenocarcinoma

Overview
Journal EJNMMI Res
Date 2023 Apr 4
PMID 37014500
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study aims to construct radiomics models based on [F]FDG PET/CT using multiple machine learning methods to predict the EGFR mutation status of lung adenocarcinoma and evaluate whether incorporating clinical parameters can improve the performance of radiomics models.

Methods: A total of 515 patients were retrospectively collected and divided into a training set (n = 404) and an independent testing set (n = 111) according to their examination time. After semi-automatic segmentation of PET/CT images, the radiomics features were extracted, and the best feature sets of CT, PET, and PET/CT modalities were screened out. Nine radiomics models were constructed using logistic regression (LR), random forest (RF), and support vector machine (SVM) methods. According to the performance in the testing set, the best model of the three modalities was kept, and its radiomics score (Rad-score) was calculated. Furthermore, combined with the valuable clinical parameters (gender, smoking history, nodule type, CEA, SCC-Ag), a joint radiomics model was built.

Results: Compared with LR and SVM, the RF Rad-score showed the best performance among the three radiomics models of CT, PET, and PET/CT (training and testing sets AUC: 0.688, 0.666, and 0.698 vs. 0.726, 0.678, and 0.704). Among the three joint models, the PET/CT joint model performed the best (training and testing sets AUC: 0.760 vs. 0.730). The further stratified analysis found that CT_RF had the best prediction effect for stage I-II lesions (training set and testing set AUC: 0.791 vs. 0.797), while PET/CT joint model had the best prediction effect for stage III-IV lesions (training and testing sets AUC: 0.722 vs. 0.723).

Conclusions: Combining with clinical parameters can improve the predictive performance of PET/CT radiomics model, especially for patients with advanced lung adenocarcinoma.

Citing Articles

MVASA-HGN: multi-view adaptive semantic-aware heterogeneous graph network for mutation status prediction.

Yang W, Yoshida S, Zhao J, Wu W, Qiang Y Quant Imaging Med Surg. 2025; 15(2):1190-1211.

PMID: 39995744 PMC: 11847186. DOI: 10.21037/qims-24-1370.


A Machine Learning Model Based on Radiomic Features as a Tool to Identify Active Giant Cell Arteritis on [F]FDG-PET Images During Follow-Up.

Vries H, van Praagh G, Nienhuis P, Alic L, Slart R Diagnostics (Basel). 2025; 15(3).

PMID: 39941297 PMC: 11817507. DOI: 10.3390/diagnostics15030367.


BATF promotes tumor progression and association with FDG PET-derived parameters in colorectal cancer.

Lu X, Liu J, Feng L, Huang Y, Xu Y, Li C J Transl Med. 2024; 22(1):558.

PMID: 38862971 PMC: 11165778. DOI: 10.1186/s12967-024-05367-5.


Subregion-specific F-FDG PET-CT radiomics for the pre-treatment prediction of EGFR mutation status in solid lung adenocarcinoma.

Wang Y, Yang G, Gao X, Li L, Zhu H, Yi H Am J Nucl Med Mol Imaging. 2024; 14(2):134-143.

PMID: 38737644 PMC: 11087292. DOI: 10.62347/DDRR4923.


Predictive value of F-FDG PET/CT radiomics for EGFR mutation status in non-small cell lung cancer: a systematic review and meta-analysis.

Ma N, Yang W, Wang Q, Cui C, Hu Y, Wu Z Front Oncol. 2024; 14:1281572.

PMID: 38361781 PMC: 10867100. DOI: 10.3389/fonc.2024.1281572.


References
1.
Devarakonda S, Morgensztern D, Govindan R . Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015; 16(7):e342-51. DOI: 10.1016/S1470-2045(15)00077-7. View

2.
McLoughlin E, Gentzler R . Epidermal Growth Factor Receptor Mutations. Thorac Surg Clin. 2020; 30(2):127-136. DOI: 10.1016/j.thorsurg.2020.01.008. View

3.
Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

4.
Hur J, Kim H, Lee J, Choi C, Lee J, Jung M . Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. Mol Cancer. 2018; 17(1):15. PMC: 5787306. DOI: 10.1186/s12943-018-0772-6. View

5.
Recondo G, Facchinetti F, Olaussen K, Besse B, Friboulet L . Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. Nat Rev Clin Oncol. 2018; 15(11):694-708. DOI: 10.1038/s41571-018-0081-4. View